V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 20213932 | 20080295 | 1.65 | 59.2 | Palliative (P) | 2017-12-25 | 2018-01-22 | HCX (Cape + Cisp + Tras) - Main | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 100206870 |
| 20213933 | 20080296 | null | 70.7 | 03 | 2017-06-05 | 2017-06-15 | HCX (Cape + Cisp + Tras) - Load | 02 | N | LANREOTIDE | 101123551 |
| 20213934 | 20080297 | 1.71 | 86.7 | Curative (C) | 2019-10-18 | 2019-10-31 | Cetuximab + FOLFIRI cycle1 | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 101652484 |
| 20213935 | 20080298 | 1.85 | 92.9 | Palliative (P) | 2018-04-18 | 2018-05-15 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101186990 |
| 20213936 | 20080299 | 0 | 61.5 | null | 2017-06-04 | 2017-06-04 | Imatinib 400mg | 02 | null | IMATINIB | 100773795 |
| 20213937 | 20080300 | 1.67 | null | Palliative (P) | 2017-01-27 | 2017-01-27 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101778503 |
| 20213940 | 20080303 | 1.8 | 93 | Palliative (P) | 2017-10-29 | 2017-10-29 | HCX (Cape + Cisp + Tras) - Load | 02 | null | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 100431809 |
| 20213941 | 20080304 | 1.59 | 0 | Curative (C) | null | 2017-02-07 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | Y | FLUOROURACIL + MITOMYCIN + RT | 101140170 |
| 20213942 | 20080305 | 1.65 | 88.7 | Curative (C) | 2019-12-06 | 2019-12-13 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | Y | FLUOROURACIL + MITOMYCIN + RT | 100788142 |
| 20213943 | 20080306 | 1.68 | 51 | Curative (C) | 2016-05-31 | 2016-06-16 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | null | FLUOROURACIL + MITOMYCIN + RT | 101641781 |
| 20213944 | 20080307 | 1.79 | 85.7 | Palliative (P) | 2018-05-29 | 2018-06-06 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 101145318 |
| 20213945 | 20080308 | 1.5 | 69.3 | Curative (C) | 2018-10-21 | 2018-11-10 | Fluorouracil+Mitomycin+RT (Anal Ca) | 02 | null | FLUOROURACIL + MITOMYCIN + RT | 101695521 |
| 20213948 | 20080309 | 1.61 | 54 | Palliative (P) | 2017-01-02 | 2017-02-03 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100241609 |
| 20213949 | 20080310 | 1.55 | 65 | Adjuvant (A) | 2018-10-25 | 2018-10-29 | Fluorouracil+Mitomycin+RT (Bladder) | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 100541208 |
| 20213950 | 20080311 | 1.68 | 46.3 | null | 2019-01-08 | 2019-01-08 | Trial Unspecified | Y | N | TRIAL | 101611032 |
| 20213952 | 20080313 | 1.75 | 122.9 | 03 | 2016-03-21 | 2016-03-21 | IMATINIB | 02 | N | IMATINIB | 100661879 |
| 20213953 | 20080314 | 1.7 | 76 | Neo-adjuvant (N) | 2018-10-09 | 2018-10-17 | Trial Unspecified | 01 | N | TRIAL | 100275037 |
| 20213954 | 20080315 | 1.7 | 48 | Palliative (P) | 2017-09-09 | 2017-09-16 | GO2 TRIAL | 01 | N | TRIAL | 100918240 |
| 20213955 | 20080316 | 1.75 | 0 | Palliative (P) | 2019-08-28 | 2019-09-02 | HCX | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100881141 |
| 20213956 | 20080317 | 1.63 | 82.8 | 03 | 2016-06-15 | 2016-06-22 | Imatinib 400mg | 02 | N | IMATINIB | 101833152 |
| 20213957 | 20080318 | 1.69 | 92.4 | Curative (C) | 2016-12-01 | 2016-12-22 | Fluorouracil+Mitomycin+RT (Anal Ca) | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 100528369 |
| 20213958 | 20080319 | 1.55 | 70.2 | Palliative (P) | 2020-02-19 | 2020-03-06 | CETUXIMAB + IRINOTECAN + MDG | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 101168861 |
| 20213959 | 20080320 | 1.67 | 61.6 | Neo-adjuvant (N) | null | 2018-04-12 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | IMATINIB | 101717821 |
| 20213960 | 20080321 | 1.63 | 59.5 | Neo-adjuvant (N) | 2017-08-20 | 2017-09-02 | Cape+Cisplatin+Trastuzumab Load | 02 | N | IMATINIB | 100422234 |
| 20213961 | 20080322 | 1.77 | 72.4 | Palliative (P) | 2017-03-11 | 2017-03-18 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | null | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100547992 |
| 20213962 | 20080323 | null | null | Palliative (P) | 2019-02-05 | 2019-02-16 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101174116 |
| 20213963 | 20080324 | 1.59 | 77.9 | Curative (C) | 2018-12-23 | 2018-12-28 | Fluorouracil+Mitomycin+RT (Anal Ca) | 02 | N | FLUOROURACIL + MITOMYCIN + RT | 100502191 |
| 20213964 | 20080325 | 1.59 | 73.2 | Palliative (P) | 2019-12-20 | 2019-12-27 | Cape+Cisplatin+Trastuzumab Load | 02 | N | TRIAL | 100897811 |
| 20213965 | 20080326 | 1.63 | 54 | Curative (C) | 2019-11-28 | 2019-11-30 | Fluorouracil+Mitomycin+RT (Anal Ca) | 02 | N | FLUOROURACIL + MITOMYCIN + RT | 101222610 |
| 20213966 | 20080327 | 1.8 | 75.3 | Palliative (P) | 2019-09-03 | 2019-09-03 | Cetuximab + FOLFIRI cycle1 | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 101042401 |
| 20213967 | 20080328 | 1.58 | 58 | 03 | 2016-09-24 | 2016-10-15 | Cape+Cisplatin+Trastuzumab Main | 02 | N | LANREOTIDE | 100611773 |
| 20213968 | 20080329 | 1.62 | 72.4 | Palliative (P) | 2019-09-30 | 2019-10-20 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 100042613 |
| 20213970 | 20080331 | 1.83 | null | Palliative (P) | 2020-01-16 | 2020-02-01 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100927406 |
| 20213971 | 20080332 | 1.62 | 66.9 | Curative (C) | 2018-08-15 | 2018-09-06 | Fluorouracil+Mitomycin+RT (Anal Ca) | 02 | null | FLUOROURACIL + MITOMYCIN + RT | 100541274 |
| 20213972 | 20080333 | 0 | 47 | Disease modification (D) | 2019-08-15 | 2019-08-23 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | LANREOTIDE | 101055746 |
| 20213974 | 20080335 | 0 | 97.2 | null | 2019-06-23 | 2019-07-08 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | null | IMATINIB | 101542634 |
| 20213975 | 20080336 | null | null | Palliative (P) | 2019-01-03 | 2019-01-03 | LANREOTIDE | 02 | N | LANREOTIDE | 100644027 |
| 20213976 | 20080337 | 1.65 | 0 | Palliative (P) | 2018-05-12 | 2018-05-19 | Imatinib 400mg | 02 | N | IMATINIB | 101500299 |
| 20213977 | 20080338 | null | null | null | 2019-07-26 | 2019-08-23 | Imatinib 400mg | 2 | null | IMATINIB | 101299076 |
| 20213978 | 20080339 | 1.73 | 78 | Palliative (P) | 2018-12-20 | 2019-01-02 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101689185 |
| 20213979 | 20080340 | 1.72 | 80.7 | null | 2016-08-16 | 2016-08-27 | HCX (Cape + Cisp + Tras) - Load | 02 | null | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100736911 |
| 20213981 | 20080341 | 1.78 | 73.4 | Adjuvant (A) | 2019-01-11 | 2019-01-20 | Fluorouracil+Mitomycin+RT (Anal Ca) | null | Y | FLUOROURACIL + MITOMYCIN + RT | 101359074 |
| 20213982 | 20080342 | 1.69 | 55.8 | Palliative (P) | 2017-11-22 | 2017-11-30 | Trial Unspecified | Y | N | TRIAL | 100280192 |
| 20213984 | 20080343 | null | null | Palliative (P) | 2019-05-12 | 2019-05-19 | GO2 TRIAL | N | N | TRIAL | 100212414 |
| 20213985 | 20080344 | 1.6 | 0 | Palliative (P) | 2018-11-21 | 2018-11-22 | CETUXIMAB + IRINOTECAN + MDG | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 101214497 |
| 20213987 | 20080346 | 0 | 88.8 | 03 | 2016-05-31 | 2016-06-13 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | IMATINIB | 101306918 |
| 20213989 | 20080348 | 1.6 | 66.7 | Disease modification (D) | 2018-02-05 | 2018-02-09 | HCX (Cape + Cisp + Tras) - Load | 02 | N | IMATINIB | 100571435 |
| 20213990 | 20080349 | 1.8 | null | Curative (C) | 2019-01-19 | 2019-02-09 | FLUOROURACIL + MITOMYCIN + RT | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 101798496 |
| 20213992 | 20080351 | 1.69 | 58 | Palliative (P) | 2017-12-16 | 2017-12-16 | GO2 TRIAL | Y | N | TRIAL | 101036397 |
| 20213995 | 20080353 | 1.7 | 75 | Palliative (P) | 2016-11-02 | 2016-11-23 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100028008 |